2.4.0.82120100 - Disclosure - Subsequent Events (Notes)truefalsefalse1false falsefalseD2013Q2YTDhttp://www.sec.gov/CIK0001113481duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_SubsequentEventsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Subsequent Events [Abstract]2false 2us-gaap_SubsequentEventsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Event</font></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 4, 2013, the Company entered into a share purchase agreement with ProFibrix and its equityholders to acquire all of the equity of ProFibrix, subject to the Company's satisfactory review of the then pending Phase 3 clinical trial results of ProFibrix's lead biologic, Fibrocaps. Following the Company's review of the Phase 3 trial results, on August 2, 2013, the Company notified ProFibrix that it wished to proceed to the closing of its acquisition of ProFibrix. The transaction closed on August 5, 2013 and, upon completion of the acquisition, ProFibrix became a wholly owned subsidiary of the Company (see note 13 &#8220;Acquisitions&#8221;).</font></div></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.No definition available.false0Subsequent EventfalseSubsequent Events (Notes)UnKnownUnKnownUnKnownUnKnowntruefalsefalseNoteshttp://www.themedicinescompany.com/role/SubsequentEventsNotes12